---
company: RELMADA THERAPEUTICS, INC.
ticker: RLMD
form: 8-K
filed: 2026-05-12
accession: 0001213900-26-055164
source: https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/
---

# Relmada Therapeutics (RLMD) earnings release, May 12, 2026

Relmada Therapeutics, Inc. (RLMD) · Form 8-K, Item 2.02 · Filed 2026-05-12 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/)

Relmada Therapeutics Reports First Quarter 2026

Financial Results and Provides Business Update

CORAL GABLES, FL – May 12, 2026 (Globe Newswire) – Relmada Therapeutics, Inc.

(Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.

“We made significant progress in the first quarter, highlighted by the robust 12-month Phase 2 data for NDV-01 in NMIBC and the successful completion of a $160 million PIPE financing, which has well-capitalized our balance sheet to fund the NDV-01 RESCUE Phase 3 program through completion,” said

Sergio Traversa,

Chief Executive Officer of Relmada Therapeutics. “We remain on track to file the NDV-01 IND and initiate the Phase 3 RESCUE registrational program in mid-2026 – a milestone that would mark a major inflection point for Relmada and for the patients we aim to serve. We believe NDV-01 has the potential to be a best-in-class therapy for patients with NMIBC and remain focused on maximizing its potential for success. To this end, in April, we filed a provisional patent application in the U.S. directed to formulations and methods of treatment for NDV-01. This application, if issued, could form the basis for worldwide patent filings, and have a term into 2047.”

“The AUA2026 Annual Meeting provides an important opportunity to introduce NDV-01 to the broader urologic community,” said

Raj S. Pruthi, MD, Chief Medical Officer – Urology of Relmada Therapeutics. “Our presentations will highlight the 12-month Phase 2 data generated to date for NDV-01, including observed complete responses and safety findings. We will also be sharing the design and rationale for the Phase 3 RESCUE program. NDV-01 is a sustained-release gemcitabine and docetaxel (Gem/Doce) designed to support streamlined, in-office administration in less than five minutes. We believe AUA2026 provides an important national forum to increase awareness and engagement within the investigator community as we approach the initiation of the RESCUE program in mid-2026.”

Upcoming AUA2026 Presentations and NDV-01 Phase

2 Data Highlights:

Relmada will present two abstracts at AUA2026 including: (1) NDV-01 Phase 2 data (12-month follow-up), and (2) the Phase 3 RESCUE program design (Clinical Trials in Progress session).

The presentations are intended to raise awareness of NDV-01 and build investigator interest in the RESCUE registrational program. Key data to be highlighted include:

NDV-01 Intellectual Property:

In April 2026, Relmada filed a provisional patent application with the United States Patent and Trademark Office (USPTO) directed to pharmaceutical formulations and methods of treatment related to NDV-01. The provisional filing has the potential to form the basis for a comprehensive world-wide patent filing program for

NDV-01. If issued, patents claiming priority to the provisional filing will be expected to have a term until April 2047.

Expected Upcoming Relmada Milestones:

Financial Results

First Quarter 2026 Financial Results²

Conference Call and Webcast Information:

Relmada will host a conference call and webcast today at 4:30 PM ET to discuss recent business progress and financial results.

Conference Call and Webcast Information:

A replay of the webcast will be available in the

Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About NDV-01

NDV-01 is a ready-to-use, sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). The formulation is engineered to provide prolonged bladder retention and controlled drug release over approximately 10 days. By forming a soft intravesical matrix, NDV-01 is designed to increase local drug exposure while limiting systemic toxicity. The treatment can be administered conveniently in an office setting in under 5 minutes without the need for anesthesia or specialized equipment. It is encompassed by multiple patent applications that if issued, could provide protection until 2047.³

About the NDV-01 Phase 2 Study

The Phase 2 study (NCT06663137) is an open-label, single-arm, single-center study evaluating the safety and efficacy of NDV-01 in patients with high-grade non-muscle invasive bladder cancer

(HG-NMIBC). Patients are treated with NDV-01 in a biweekly induction phase, followed by monthly maintenance for up to one year. Patients were evaluated at 3-month intervals using cystoscopy and cytology, with biopsies performed at the treating physician’s discretion.

Time-to-event endpoints, including complete response (CR) and event free survival (EFS) rates, were analyzed as landmark events and using

Kaplan–Meier (KM) analysis. The primary efficacy endpoints are safety and CR rate at 12 months, and secondary efficacy endpoints are duration of response (DOR) and EFS. Treatment-related adverse events (TRAEs) were graded according to CTCAE v5.0 (Common Terminology

Criteria for Adverse Events, version 5.0).

About the NDV-01 Phase 3 RESCUE Registrational Pathways:

Relmada has received written feedback from the

U.S. Food and Drug Administration (FDA) confirming alignment on two registrational development pathways for NDV-01, including study design, patient populations and primary endpoints. IND filing and program initiation remain on track for mid-2026.

Registration Pathway 1 – An open-label single-arm trial in second line (2L) BCG-unresponsive NMIBC with carcinoma in situ (CIS) patients who are currently refractory... (truncated)th

CIS who fail first line (1L) therapies, which we estimate to affect ~5,000 patients/year in the US, have few, if any, effective treatment alternatives to radical cystectomy. The primary endpoint of the study is complete response (CR) rate at any time.

Registrational Pathway 2 – An open label randomized controlled trial in intermediate-risk NMIBC of adjuvant therapy following TURBT (Transurethral Resection of Bladder Tumor,

NDV-01 vs. observation). There are no approved adjuvant treatments for intermediate risk NMIBC, which we estimate affect ~75,000 patients/year in the US. The primary endpoint of the study is disease free survival (DFS).

About NMIBC

NMIBC represents 75-80% of all bladder cancer cases and is associated with high recurrence (50 – 80% over 5 years). With over 744,000 prevalent cases in the U.S. and limited treatment options, the market opportunity is significant. High-grade BCG-unresponsive disease represents one of the most difficult-to-treat

NMIBC subtypes, with limited bladder-sparing options. Intermediate-risk NMIBC in the adjuvant setting has no currently approved therapies.

NDV-01 has the potential to serve as a frontline or salvage therapy and could be applicable across multiple NMIBC subtypes.

About Sepranolone and GABA Modulation

Sepranolone, a synthetic isoallopregnanolone, selectively modulates GABA

A receptors by antagonizing allopregnanolone (ALLO), without disrupting GABA signaling. It targets disorders linked to excess GABAergic activity such as Prader-Willi syndrome, Tourette syndrome, and Obsessive-Compulsive Disorder (OCD).

More than 335 patients have been treated with sepranolone in clinical trials to date, with an excellent safety profile.⁴

About Prader-Willi Syndrome (PWS)

PWS is a rare genetic disorder caused by chromosomal deletions on chromosome 15, leading to neurodevelopmental and behavioral complications. Global prevalence is estimated to be 350,000-400,000 patients. Current treatments address symptoms but do not modify the underlying neurobehavioral pathology.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Forward-Looking Statements:

The Private Securities Litigation Reform Act of

1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute

“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities

Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”,

“will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”, and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential for Relmada’s product candidates to fail to progress, potential for Phase 2 NDV-01 data to fail to continue to deliver positive results supporting further development, potential for clinical trials to fail to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of interim or top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone, or that future NDV-01 and/or sepranolone clinical results will be acceptable to the FDA, failure to secure adequate NDV-01 and/or sepranolone drug supply, failure of pending patent applications to result in issued patents, or issued patents being challenged and invalidated by third parties or not providing us with any competitive advantages, the Company’s cash runway and sufficiency of the Company’s cash resources and uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein are not a complete list.

Investor Contact:

Brian Ritchie

LifeSci Advisors britchie@lifesciadvisors.com

Media Inquiries:

Corporate Communications media@relmada.com⁵

Relmada Therapeutics, Inc.

Condensed Consolidated Balance Sheets⁶

Relmada Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)⁷

Relmada Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders’

Equity

(Unaudited)⁸

Relmada Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)⁹

## Financial statements

### Income Statement (Three months ended — (Unaudited))

| | Three months ended – March 31, – 2026 | Three months ended – March 31, – 2025 |
|---|---:|---:|
| Operating expenses: | Research and development | 8,087,845 | 11,951,023 |
| Operating expenses: | General and administrative | 11,373,909 | 6,267,412 |
| Operating expenses: | Total operating expenses | 19,461,754 | 18,218,435 |
| Operating expenses: | Loss from operations | -19,461,754 | -18,218,435 |
| Other income: | Interest/investment income, net | 959,762 | 440,287 |
| Other income: | Realized (loss)/gain on short-term investments | -9,867 | 62,952 |
| Other income: | Unrealized (loss)/gain on short-term investments | -540,097 | 155,731 |
| Other income: | Total other income, net | 409,798 | 658,970 |
| Other income: | Net loss | -19,051,956 | -17,559,465 |
| Other income: | Loss per common share – basic and diluted | -0.22 | -0.58 |
| Other income: | Weighted average number of common shares outstanding – basic and diluted | 86,596,873 | 30,408,890 |

### Balance Sheet (Condensed Consolidated Balance Sheets)

| | As of – March 31, – 2026 (Unaudited) | As of – December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 9,776,400 | 3,496,540 |
| Current assets: | Short-term investments | 224,186,743 | 89,509,710 |
| Current assets: | Prepaid expenses | 1,380,151 | 977,721 |
| Current assets: | Total current assets | 235,343,294 | 93,983,971 |
| Current assets: | Other assets | 19,500 | 19,500 |
| Current assets: | Total assets | 235,362,794 | 94,003,471 |
| Current liabilities: | Accounts payable | 5,731,401 | 1,568,944 |
| Current liabilities: | Accrued expenses | 7,160,233 | 4,861,583 |
| Current liabilities: | Total current liabilities | 12,891,634 | 6,430,527 |
| Current liabilities: | Stock appreciation rights | 3,738,583 | 1,060,931 |
| Current liabilities: | Total liabilities | 16,630,217 | 7,491,458 |
| Stockholders’ Equity: | Common stock, $0.001 par value, 150,000,000 shares authorized, 104,890,223 and 73,333,622 shares issued and outstanding, respectively | 104,890 | 73,333 |
| Stockholders’ Equity: | Additional paid-in capital | 935,946,841 | 784,705,878 |
| Stockholders’ Equity: | Accumulated deficit | -717,319,154 | -698,267,198 |
| Stockholders’ Equity: | Total stockholders’ equity | 218,732,577 | 86,512,013 |
| Stockholders’ Equity: | Total liabilities and stockholders’ equity | 235,362,794 | 94,003,471 |

### Cash Flow (Three months ended — Condensed Consolidated Statements of Cash Flows (Unaudited))

| | Three months ended – March 31, – 2026 | Three months ended – March 31, – 2025 |
|---|---:|---:|
| Cash flows from operating activities | Net loss | -19,051,956 | -17,559,465 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock-based compensation | 956,186 | 3,572,769 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock appreciation rights compensation | 2,677,652 | 3,038 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Issuance of restricted common stock |  | 905,226 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Realized loss/(gain) on short-term investments | 9,867 | -62,952 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Unrealized loss/(gain) on short-term investments | 540,097 | -155,731 |
| Change in operating assets and liabilities: | Prepaid expenses | -402,430 | 290,051 |
| Change in operating assets and liabilities: | Accounts payable | 1,762,457 | -2,865,553 |
| Change in operating assets and liabilities: | Accrued expenses | -1,559,361 | -2,194,416 |
| Change in operating assets and liabilities: | Net cash used in operating activities | -15,067,488 | -18,067,033 |
| Cash flows from investing activities | Purchase of short-term investments | -149,517,480 | -487,916 |
| Cash flows from investing activities | Sale of short-term investments | 14,290,483 | 15,847,629 |
| Cash flows from investing activities | Net cash (used in)/provided by investing activities | -135,226,997 | 15,359,713 |
| Cash flows from financing activities | Proceeds from issuance of common stock | 159,999,996 |  |
| Cash flows from financing activities | Payment of fees for issuance of common stock | -3,360,000 |  |
| Cash flows from financing activities | ATM Fees | -65,651 |  |
| Cash flows from financing activities | Net cash provided by financing activities | 156,574,345 |  |
| Cash flows from financing activities | Net increase/(decrease) in cash and cash equivalents | 6,279,860 | -2,707,320 |
| Cash flows from financing activities | Cash and cash equivalents at beginning of the period | 3,496,540 | 3,857,026 |
| Cash flows from financing activities | Cash and cash equivalents at end of the period | 9,776,400 | 1,149,706 |
| Non-cash investing and financing activities: | Cashless exercise of warrants for common stock | -2,082 |  |
| Non-cash investing and financing activities: | Fees for issuance of common stock included in accounts payable | 2,400,000 |  |
| Non-cash investing and financing activities: | Fees for issuance of common stock included in accrued expenses | 3,858,011 |  |
